The role focuses on developing strategy and executing tactics to promote VYVGART Hytrulo for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Base: $128,000.00 - $176,000.00 USD annually; Bonus/Equity: Eligible for short-term and long-term incentive programs; Benefits: Comprehensive package including retirement savings plans and health benefits
Must-have
Nice-to-have
Not specified